Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.typeArtigo de periódicopt_BR
dc.titleQuality Of Life In Patients Randomized To Receive A Bone Marrow Or A Peripheral Blood Allograft.pt_BR
dc.contributor.authorDe Souza, Carmino Antoniopt_BR
dc.contributor.authorDurães, Margareth I Cpt_BR
dc.contributor.authorVigorito, Afonso Celsopt_BR
dc.contributor.authorPenteado Aranha, Francisco Josépt_BR
dc.contributor.authorOliveira, Gislaine Barbosapt_BR
dc.contributor.authorDe Brito Eid, Kátia Apt_BR
dc.contributor.authorZulli, Robertopt_BR
dc.contributor.authorCristina, Elianapt_BR
dc.contributor.authorMiranda, Martinspt_BR
dc.contributor.authorBotega, Neury Josépt_BR
unicamp.authorCarmino Antonio De Souza, Bone Marrow Transplantation Unit, State University of Campinas, Brazil. carmino@unicamp.brpt_BR I C Durães,pt Celso Vigorito,pt José Penteado Aranha,pt Barbosa Oliveira,ptátia A De Brito Eid,pt Zulli,pt Cristina,pt Miranda,pt José Botega,pt
dc.subjectBone Marrow Transplantationpt_BR
dc.subjectFollow-up Studiespt_BR
dc.subjectGraft Vs Host Diseasept_BR
dc.subjectMiddle Agedpt_BR
dc.subjectPeripheral Blood Stem Cell Transplantationpt_BR
dc.subjectProspective Studiespt_BR
dc.subjectQuality Of Lifept_BR
dc.subjectTransplantation, Homologouspt_BR
dc.description.abstractQuality of life (QOL) is an important clinical end-point to be considered in the late follow-up of patients treated with allogeneic bone marrow (BM) or peripheral blood progenitor cell (PBPC) transplantation. To assess the QOL in a group of survivors of hematologic malignancies who had been enrolled in a prospective randomized trial comparing allogeneic BM with PBPC. Sixty randomized patients had been enrolled in a study comparing BM with PBPC graft during 1995-99. At the time of this QOL study, 30 were alive and 26 (13 BM and 13 PBPC) were eligible. Clinical and demographic data were collected and psychometric instruments (WHOQOL-100 and the Hospital Anxiety and Depression Scale HAD) were used. Non-parametric and univariate analyses were performed. The PBPC recipients had more chronic graft-versus-host disease (p=0.03) and were on immunosuppressive treatment for a longer period (p=0.02). The WHOQOL-100 analysis demonstrated significant differences between groups with more favorable results in the BM group in the facets of Pain and Discomfort (p=0.03), Mobility (p=0.02) and Daily Living Activities (p=0.03). According to the patients' spontaneous responses, 8 individuals (6 in the PBPC group) believed that their QOL had worsened. With the limitations of a small randomized study, these findings suggest a lower QOL in recipients of allogeneic PBPC than in recipients of BM grafts, probably due to the frequency and severity of chronic graft-versus-host disease. This need to be confirmed in a large international trial.en
dc.identifier.citationHaematologica. v. 87, n. 12, p. 1281-5, 2002-Dec.pt_BR
dc.description.provenanceMade available in DSpace on 2015-11-27T12:49:26Z (GMT). No. of bitstreams: 1 pmed_12495902.pdf: 106769 bytes, checksum: 4a1eaecd641bb8a3707a90352c78a360 (MD5) Previous issue date: 2002en
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
File SizeFormat 
pmed_12495902.pdf104.27 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.